Groupama Asset Managment Increases Stock Position in Johnson & Johnson $JNJ

Groupama Asset Managment raised its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 13.9% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 39,214 shares of the company’s stock after purchasing an additional 4,777 shares during the period. Groupama Asset Managment’s holdings in Johnson & Johnson were worth $5,977,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Johnson Financial Group Inc. lifted its stake in Johnson & Johnson by 2.2% during the 2nd quarter. Johnson Financial Group Inc. now owns 62,672 shares of the company’s stock valued at $9,573,000 after acquiring an additional 1,349 shares during the period. Crabel Capital Management LLC bought a new position in Johnson & Johnson during the second quarter valued at approximately $268,000. Financial Avengers Inc. boosted its holdings in Johnson & Johnson by 1.8% in the second quarter. Financial Avengers Inc. now owns 49,345 shares of the company’s stock worth $7,537,000 after purchasing an additional 874 shares during the last quarter. Elgethun Capital Management grew its position in Johnson & Johnson by 6.3% in the 2nd quarter. Elgethun Capital Management now owns 4,062 shares of the company’s stock worth $620,000 after purchasing an additional 239 shares during the period. Finally, GM Advisory Group LLC raised its stake in Johnson & Johnson by 4.6% during the 2nd quarter. GM Advisory Group LLC now owns 14,213 shares of the company’s stock valued at $2,171,000 after buying an additional 620 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Down 0.3%

NYSE JNJ opened at $206.89 on Friday. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $207.81. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. The company has a market capitalization of $498.46 billion, a P/E ratio of 19.97, a price-to-earnings-growth ratio of 2.19 and a beta of 0.38. The stock’s 50-day moving average price is $191.33 and its 200-day moving average price is $173.36.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The company had revenue of $24.02 billion during the quarter. On average, equities research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is presently 50.19%.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.16% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Johnson Rice set a $190.00 price objective on Johnson & Johnson and gave the stock a “hold” rating in a report on Wednesday, October 22nd. Argus set a $210.00 target price on Johnson & Johnson in a research report on Wednesday, October 15th. Daiwa Capital Markets upgraded Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 price target for the company in a research note on Monday, October 20th. Wall Street Zen upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Saturday, September 13th. Finally, Loop Capital set a $190.00 price objective on shares of Johnson & Johnson in a report on Wednesday, October 22nd. Four research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus target price of $201.05.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.